Nucleome Therapeutics

An Oxford biotech that reads the 'dark matter' of the human genome to find new drug targets for autoimmune diseases.

About Nucleome Therapeutics

Nucleome Therapeutics studies the large part of our DNA that does not code for proteins, often called the dark matter of the genome. It combines 3D maps of how the genome folds with machine learning to link genetic differences to the genes and diseases they affect. Its first focus is immune cells and autoimmune diseases.

The company says it aims to decode the dark matter of the human genome to discover first-in-class precision medicines, and to find new ways to treat patients in need.

Nucleome was founded in 2019 and is based in Oxford. It started in the University of Oxford's BioEscalator and later moved to the Schrodinger Building at the Oxford Science Park. Its chief executive and co-founder is Dr Danuta Jeziorska.

A BioEscalator note said it had grown from one employee to 20 (undated, so likely out of date). Combining biology, genetics and data science means students from several subjects can fit in.

We found a scientist vacancy listed for the Oxford site, but no sourced internship or graduate scheme. Check its own careers page.

What they do

• {'desc': 'Cell-type-specific maps of how DNA is folded.', 'title': '3D genome mapping'}
• {'desc': 'Linking genetic variants to genes and disease.', 'title': 'Target discovery'}
• {'desc': 'Drug discovery focused on immune-driven disease.', 'title': 'Autoimmune programmes'}

Key facts

• Founded 2019 in Oxford
• CEO and co-founder: Dr Danuta Jeziorska
• Moved from the BioEscalator to the Oxford Science Park
• Focus: autoimmune disease (immune cells)

Website: www.nucleome.com